In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the role of inflammatory signaling pathways in lower-risk myelodysplastic syndromes (MDS) versus higher-risk MDS, and treatment approaches for each. Dr Sallman also highlights the value of targeting these pathways in patients with clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) to prevent disease progression, and ongoing trials in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.